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Abstract
Obesity is a chronic inflammatory condition characterized by activation and infiltration of proinflammatory immune cells
and a dysregulated production of proinflammatory cytokines. While known as a key regulator of immune natural killer (NK)
cell function and development, we have recently demonstrated that reduced expression of the cytokine Interleukin-15 (IL-
15) is closely linked with increased body weight and adiposity in mice and humans. Previously, we and others have shown
that obese individuals have lower circulating levels of IL-15 and NK cells. Lean IL-15 overexpressing (IL-15 tg) mice had an
accumulation in adipose NK cells compared to wildtype and NK cell deficient obese IL-15
2/2 mice. Since IL-15 induces
weight loss in IL-15
2/2 and diet induced obese mice and has effects on various lymphocytes, the aim of this paper was to
determine if lymphocytes, particularly NK cells, play a role in IL-15 mediated weight loss. Acute IL-15 treatment resulted in
an increased accumulation of NK, NKT, and CD3
+ T cells in adipose tissue of B6 mice. Mice depleted of NK and NKT cells had
similar weight loss comparable to controls treated with IL-15. Finally, IL-15 treatment induces significant weight loss in
lymphocyte deficient RAG2
2/2cc
2/2 mice independent of food intake. Fat pad cross-sections show decreased pad size with
cytokine treatment is due to adipocyte shrinkage. These results clearly suggest that IL-15 mediates weight loss independent
of lymphocytes.
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Introduction
Obesity is defined as an accumulation of adipose tissue and is
associated with systemic chronic inflammation [1]. Altered
immune responses in obese individuals have been recently linked
to the development of comorbidities such as insulin resistance and
dyslipidemia [1–3]. As an inflammatory condition, obesity is
characterized by increased infiltration of various immune cells into
adipose tissue, such as M1 polarized macrophages, as well as
a decrease in anti-inflammatory immune cells such as M2
polarized macrophages [2,4]. As prevalence rates and its
associated chronic conditions continue to rise, insights into the
pathophysiology related to obesity and the immune contribution
to metabolic disease development is essential in formulating novel
therapeutic strategies in treating obesity and its associated
comorbidities.
Although several reports have examined the role of altered
adipose macrophage phenotypes in obese individuals [2,4,5],
recent studies have also demonstrated associations between obesity
and alterations in lymphocyte populations. In obese adipose tissue,
increased CD8
+ T cells and decreased CD4
+ and anti-inflamma-
tory regulatory T cells have been found [6,7]. Obese adipose tissue
has been shown to activate CD8
+ T cells leading to macrophage
recruitment and activation [7]. As well, natural killer T (NKT)
cells have been shown to play a role in metabolic abnormalities
associated with obesity [8,9]. Lastly, innate immune natural killer
(NK) cells have reduced cytotoxicity in obese animals compared to
lean controls [10]. Alterations in these lymphocyte populations in
obese individuals suggest the presence or absence of these cell
types may play a role in weight regulation. Since a dysregulation in
the production of proinflammatory cytokines also contributes to
this inflammatory state through such factors as interleukin-6 (IL-6)
and tumor necrosis factor –a (TNF-a) [11], determining the role of
these cytokines in regulating immune lymphocyte responses in
obesity is also essential in formulating treatments for obese
individuals.
While best known as a key regulator of immune natural killer
cell function and development [12,13], we and others have
recently demonstrated that reduced expression of the cytokine
Interleukin-15 (IL-15) is closely linked with increased body weight
and adiposity in both mice and humans [14–19]. Previous work
has shown that IL-15 treatment causes a significant decrease in
adipose tissue mass in normal weight [19,20] and obese rodents
[18], reduces lipoprotein lipase expression [18], and may play
a role in lipid oxidation [21,22]. We have previously observed that
over expression of IL-15 (IL-15 tg) in mice was associated with
a lean body condition, while mice lacking IL-15 (IL-15
2/2) gained
significantly more weight, developing an obese phenotype when
compared to control C57BL/6 (B6) mice. Also, we found that IL-
15 tg mice had increased percentage of NK cells found in adipose
tissue compared to normal weight B6 mice and their heavier NK
cell deficient IL-15
2/2 counterparts [14]. As well, obese
individuals and mice placed on high fat diets have decreased
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have also demonstrated that IL-15 treatment induces weight loss
in diet-induced obese mice and in IL-15
2/2 mice, which has also
been shown to reconstitute NK cell populations [14,24]. As well,
IL-15 is known to activate other lymphocytes such as NKT cells
[25,26] and T cells [26,27]. Whether NK cells and/or other
lymphocytes contribute to the weight loss effects exerted by IL-15
treatment has yet to be determined.
In this study, we sought to determine if NK cells mediate weight
loss in IL-15 treated animals. We first determined if NK cells,
along with other lymphocytes such as NKT and T cells,
accumulate in adipose tissue with acute IL-15 treatment in control
B6 mice. In order to determine if IL-15 induces weight loss
indirectly via NK cell activation, we depleted mice of NK cells
using a NK1.1 cell depleting antibody, treated with IL-15, and
monitored for weight loss. In order to determine the importance of
lymphocyte activation via IL-15 treatment, we also employed the
use of the RAG2
2/2cc
2/2 mouse model, which has no
lymphocytes and lacks the c-receptor subunit. Altogether, these
experiments will determine the role of lymphocytes, specifically
NK cells, in IL-15 regulation of adipose tissue.
Methods
Ethics
All animal experiments were approved by the Animal Research
Ethic Board (AREB) of McMaster University. The AREB
approval number is: 10-02-12.
Animals
Sixteen week old C57BL/6 (B6) female mice were purchased
from Charles River Laboratory (Quebec, Canada). Female
lymphocyte deficient Balb/c RAG-2
2/2cc
2/2 mice were bred
from breeding pairs given as a gift by M. Ito (Central Institute for
Experimental Animals, Kawasaki, Japan) and maintained at
McMaster University’s Central Animal Facility. Null mutation of
the RAG2 gene prevents B and T lymphocyte development in
these mice, while absence of the c-chain subunit prevents NK cell
maturation. Mice were caged in groups of five and maintained
under controlled lighting (12:12 L:D) and temperature (22uC) with
ad libitum access to a low fat irradiated chow diet containing 18.6%
protein, 6.2% fat, and 3.5% fiber (2918, Tekland Global Diets,
Indianapolis, IN) and water.
Delivery and Detection of IL-15 and NK1.1
+ Cell
Depletion Experiment
Body weights and food consumption were monitored daily from
the onset of treatment until mice were sacrificed. Food consump-
tion was measured for a period of five consecutive days.
Preweighed food was placed in food hoppers and measured daily
on a per-cage basis. Food intake was recorded as grams consumed
per gram of mouse per day. Percentage of weight loss was
recorded when mice were delivered either an Ad-expressing
human IL-15 vector, Opt.hIL-15 (‘‘AdIL-15’’), or an empty
adenoviral vector (‘‘AdControl’’) as previously described [28].
Briefly, an 18-aa optimized signal peptide was inserted upstream of
a mature hIL-15 gene by multi-step polymerase chain reactions
(PCRs) using primers provided by the Molecular Biology Institute
(McMaster University). After the 402-bp PCR product was
isolated (Opt.hIL-15), cloned into expression vectors using KpmI
and XhoI sites, Opt-hIL-15 was inserted into the adenoviral shuttle
vector pDC316 and subsequently generated Ad-Op-hIL-15
pDC316 in the Robert E. Fitzhenry Vector Laboratory (McMas-
ter Immunology Research Centre, McMaster University) [28].
B6 mice and RAG-2
2/2cc
2/2 mice were administered with
5610
8 pfu AdIL-15, AdControl, or 200 ml PBS via IV tail
injections on day 0, 2, and 4 (n=5 per group). For the NK1.1
+
cell depletion experiment, B6 mice were injected intraperitoneally
with 200 mg of anti-mouse NK1.1 antibody (PK136 mouse
immunoglobulin G2a hybridoma HB191; ATCC) daily for two
days prior to AdIL-15 treatment and subsequently every three
days post treatment (n=7 per group). Mice were anaesthetized
and sacrificed on day 8. Prior to sacrifice, blood was collected
through the abdominal aorta and centrifuged at 5,000 rpm for 10
minutes to collect serum. Human IL-15 levels were quantified
from serum using hIL-15 DuoSet ELISA kit (R&D Systems,
Minneapolis, MN, USA).
Adipose Tissue Collection, Histology, and Cell
Quantification
Visceral gonadal fat pads from RAG-2
2/2cc
2/2 mice were
weighed and fixed in paraformaldehyde. Tissues were then
embedded in paraffin, and two cross-sections per mouse were
stained with hematoxylin and eosin (H&E). For each cross section,
8 fields of view were quantified for cell areas using AxioVision
software (created by Carl Zeiss MicroImaging).
Cell Isolation from Fat Tissue for FACS Analysis
Weighed visceral gonadal fat pads from B6 mice were isolated,
washed in PBS, minced, and digested in collagenase A (Roche
Applied Science, Laval, Quebec, Canada) and 0.025 mg/ml
DNase (Roche Applied Science, Laval, Quebec, Canada) for
30 min at 37uC. The cell suspension was filtered through
a 100 mm, followed by a 70 mm and 40 mm cell strainer to
remove tissue particulate. This solution was then centrifuged for
10 min at 1,200 rpm at 4uC. The supernatant, which included any
remaining adipocytes, was discarded and the stromal vascular
fraction was resuspended in ACK lysis buffer to remove red blood
cells, and washed in PBS. Cells were counted using a hemocytom-
eter and resuspended in a 0.2% bovine serum albumin PBS
solution for FACS analysis. Five-hundred thousand cells per well
were plated in a 96 well plate. After cells were washed and blocked
using CD16/CD32 antibody (eBioscience, San Diego, CA), they
were surfaced stained with fluorescein isothiocyanate–, alexa fluor
700-, and phycoerythrin-conjugated anti-mouse CD45.2 (clone
104, eBioscience), CD3 (clone 17A2, eBioscience), and NK1.1
(clone PK136, BD Pharmingen) antibodies, respectively. Stained
cells were analyzed on a LSRII flow cytometer collecting 50,000
gated events and FlowJo flow cytometry analysis software.
Statistics
All statistical analyses were performed using Graph Pad Prism
4. The results are expressed as mean 6 SEM. Data were analyzed
using one-way ANOVA followed by Tukey’s post hoc multiple
comparisons test for 3 group comparisons, while Student t-test was
used for 2 group comparisons. Significance is indicated when
p,0.05.
Results
Acute IL-15 Treatment Results in an Accumulation of NK,
NKT, and T Cells in Adipose Tissue
Since IL-15 is inextricably linked to NK cell function, we
wanted to determine if an association between IL-15 mediated
weight loss and an accumulation of NK cells in visceral gonadal fat
occur in B6 mice given an acute dose of IL-15. Sixteen week old
B6 mice had similar body weights between groups prior to
IL-15 and Obesity
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more weight, had sustained serum hIL-15 expression, and had
higher cell numbers in the stromal vascular fraction of digested
visceral fat on a per gram basis compared to mice given either
AdControl or PBS (Figure 1A–C). Flow cytometric analysis
revealed that IL-15 treated animals had an increase in the
percentage of leukocytes (CD45
+), T (CD3
+), NK (CD3
2NK1.1
+)
and NKT (CD3
+NK1.1
+) cells in visceral adipose tissue compared
to controls (Figure 2). Similarly, peripheral leukocytes, T, NK, and
NKT cells were also significantly elevated in spleens of IL-15
treated mice compared to controls (data not shown).
IL-15 Treatment Induces Weight Loss Independent of NK
and NKT Cells
Since IL-15 treatment results in an accumulation of NK cells in
adipose tissue in B6 mice (Figure 2), we wanted to verify whether
weight loss was a direct effect of IL-15 or mediated indirectly by
activated NK cells. In figure 3, we show that the NK1.1
+ cell
depleting antibody is effective in depleting NK and NKT cells
from adipose tissue (Figure 3A, B). We found no significant
difference in the percentage of weight loss in B6 mice treated with
AdIL-15 compared to those depleted of NK and NKT cells
(Figure 3C, Table 2).
Interleukin-15 Treatment Induces Weight Loss in the
Absence of Lymphocytes
Since acute IL-15 treatment resulted in an accumulation of
other lymphocytic cells such as T cells, we utilized lymphocyte
deficient RAG2
2/2cc
2/2 mice. These mice had similar body
weights between groups prior to treatment (Table 1). Mice treated
with AdIL-15 lost significantly more weight compared to
AdControl or PBS treated animals (Figure 4A). Treatment of
these mice with AdIL-15 clearly showed a marked difference in the
size and weight of the abdominal visceral gonadal fat pad
compared to naı ¨ve and vehicle controls (Figure 4B, C). These
differences were not attributed to altered food consumption
(Figure 4D).
Table 1. Characteristics of mice before and after IL-15
treatment.
Treatment Groups
Measure PBS AdControl AdIL-15
Before Treatment
(B6 Mice)
25.8061.55 26.3460.78 25.3260.82
After Treatment
(B6 Mice)
25.8261.55 26.4060.78 22.3560.84***
Before Treatment
(Rag2
2/2cc
2/2
Mice)
40.6262.76 37.7261.47 39.3663.61
After Treatment
(Rag2
2/2cc
2/2
Mice)
41.3162.71 37.7761.58 30.9162.76**
Data are presented as mean 6 SEM. Body weights expressed as grams. Asterisks
used to denote significance using a paired Student t-test comparing before and
after body weights within the same group.
**P,0.01,
***P,0.001.
doi:10.1371/journal.pone.0039553.t001
Figure 1. Acute interleukin-15 administration results in weight loss and increased cell number in visceral adipose tissue of B6 mice.
(A) Bar graph shows percentage of weight loss in female B6 mice treated i.v. with either phosphate-buffered saline (PBS), an empty adenoviral
construct not expressing IL-15 (Ad-Control), or IL-15 expressing adenoviral construct (AdIL-15). (B) Serum collected on day 8 was analyzed for IL-15
expression using a hIL-15 DuoSet ELISA kit. (C) The cells referred to are the number of cells in the stromal vascular fraction from digested adipose
tissue in each group. The y-axis refers to the number of cells (610
6) counted from the stromal vascular fraction per gram of digested visceral gonadal
adipose tissue shown in bar graph (n=5 per group). **P,0.01, ***P,0.001.
doi:10.1371/journal.pone.0039553.g001
IL-15 and Obesity
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+, NK, NKT, and CD3
+ T cell accumulation in visceral adipose tissue in B6
mice. Analysis of (A) CD45
+,( C) CD3
+ (T), (E) CD3
2NK1.1
+ (NK), and (G) CD3
+NK1.1
+ (NKT) cell populations in visceral gonadal adipose tissue from
PBS, AdControl, and AdIL-15 treated animals. The percentage of (B) CD45
+,( D) CD3
+ (T), (F) CD3
2NK1.1
+ (NK), and (H) CD3
+NK1.1
+ (NKT) cell
populations are represented as a bar graphs (n=5 per group). ***P,0.001.
doi:10.1371/journal.pone.0039553.g002
Figure 3. Treatment with interleukin-15 induces weight loss in NK1.1
+ cell depleted B6 mice. Analysis of CD3 and NK1.1 cells gated from
a CD45.2
+ population in (A) AdIL-15 treated B6 mice and (B) NK1.1
+ depleted AdIL-15 treated mice in visceral gonadal adipose tissue. (C) Bar graph
shows weight loss in female treated mice (n=7 per group).
doi:10.1371/journal.pone.0039553.g003
IL-15 and Obesity
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Since we observed that IL-15 has significant effects on fat mass
(Figure 4), we then examined cross sections of abdominal fat pads
to assess if IL-15 treatment may be attributed to decreased cell size
and fat content. These sections reveal shrunken adipocytes
resulting in a lower cell area in AdIL-15-treated RAG2
2/2cc
2/
2 mice compared to both the Ad-Control and PBS groups
(Figure 5). This suggests that the effects of IL-15 on adiposity are
not mediated by lymphocytes and occur independently of
signaling through the common-c-chain.
Discussion
Results from this paper show that acute IL-15 administration
results in weight loss and an accumulation of NK, NKT, and
CD3
+ T cells in visceral adipose tissue in B6 mice. Previously, we
have shown that IL-15 tg mice, which remain lean over time, have
a significant increase in the percentage of NK cells found in
adipose tissue compared to control B6 mice and IL-15
2/2 mice
[14]. Since an accumulation of NK cells is associated with lean
body weight and the effects of IL-15 are inextricably linked with
NK cell function, we utilized a NK1.1 depleting antibody to
determine whether IL-15 mediates weight loss directly or in-
directly through NK and/or NKT cells in B6 mice. To determine
if IL-15 mediates weight loss through other lymphocyte popula-
tions such as T cells, we utilized the lymphocyte deficient RAG2
2/
2cc
2/2 mouse model. IL-15 treatment resulted in weight loss,
decreased visceral fat weight, and shrunken adipocytes in RAG2
2/
2cc
2/2 mice suggesting that this cytokine may directly affect
adipocytes by signaling through other receptor subunits excluding
the common-c-chain.
Immune cell populations and their contribution to metabolic
disease development in obesity have garnered a great deal of
interest; however, whether immune cells play a role in weight
regulation and adiposity has not been thoroughly examined.
Lymphoid cells are in close proximity to adipocytes in various
locations such as bone marrow, perinodal adipose tissue
surrounding lymph nodes, and subcutaneous and visceral adipose
sources [29,30]. This close contact provides opportunity for cross
talk between these two cell types. Secretion of various adipokines
Table 2. Characteristics of mice before and after IL-15
treatment.
Treatment Groups
Measure AdIL-15
AdIL-15+NK1.1
Depletion
Before Treatment
(B6 Mice)
29.1862.65 29.3461.84
After Treatment
(B6 Mice)
25.0962.49** 25.9161.93***
Data are presented as mean 6 SEM. Body weights expressed as grams. Asterisks
used to denote significance using a paired Student t-test comparing before and
after body weights within the same group.
**P,0.01,
***P,0.001.
doi:10.1371/journal.pone.0039553.t002
Figure 4. IL-15 induces weight loss independent of lymphocytes and in the absence of the common gamma chain (cc). (A) Percentage
of weight loss represented as a bar graph. (B) Picture shows excised visceral gonadal fat taken from representative female naı ¨ve, Ad-Control, and
AdIL-15 treated RAG2
2/2cc
2/2 mice. (C) Visceral gonadal fat pad in grams shown as a bar graph (n=5 per group). (D) Food consumed per gram of
mouse monitored for 5 consecutive days (n=5 per group). *P,0.05, ***P,0.001.
doi:10.1371/journal.pone.0039553.g004
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lymphocyte activity [6,7,31–33]. We were interested in determin-
ing whether factors that regulate fat mass, such as IL-15, influence
lymphocytes within adipose tissue and affect adipocyte size and fat
mass through their activation. The effects of IL-15 on NK, NKT,
and T cells include: to promote the development, survival, and
activation of NK and NKT cells [13,25,26,34,35]; control the
induction of CD4
+ memory T cells, as well as the survival and
proliferation of activated naı ¨ve and memory CD8
+ T cells
[26,27,34]; and induce interferon-gamma (IFN-c) production,
cytotoxicity, and perforin/granzyme expression in both NK cells
and CD8
+ T cells and TNF-a in CD8
+ T cells [12,25,35,36].
Nevertheless, the actual function of these cell types in lean adipose
tissue is unknown.
In vitro studies have shown that IL-15 directly affects adipose
tissue using cultured adipocytes. Recombinant IL-15 treatment
was shown to inhibit preadipocyte differentiation and lipid
deposition using the murine adipogenic 3T3-L1 cell line [37].
Similar results were shown in lipoaspirate-derived human
adipocytes treated with IL-15 at time of differentiation [14].
Inhibition of preadipocyte differentiation is associated with
increased mRNA expression of calcineurin [38] and/or alterations
in Signal transducers and activator of transcription 5 (STAT5)
expression [39]. As well, IL-15 administration has been recently
shown to affect lipid content in mature differentiated adipocytes in
vitro, suggesting that IL-15 directly affects adipocytes independent
of lymphocytes [39].
It has been previously shown, using ribonuclease protection
assays, that mRNA for all three IL-15 receptor signaling subunits
(a, b, c) are present in white adipose tissue, suggesting that
circulating IL-15 is capable of directly signaling in adipocytes [18].
IL-15 signals through a heterotrimeric receptor complex, in-
cluding a b subunit shared with IL-2 and a c-chain subunit shared
with other interleukins (IL-2, -4, -7, -9, and -21). The third unique
a subunit confers specificity and high affinity binding of IL-15 to
this complex [40,41]. Studies have shown that IL-15 signals
differently in immune lymphocytes compared to myleiod popula-
tions [42,43, Reviewed in 41]. The mechanism of IL-15 signaling
in adipocytes is currently unknown.
The lymphocyte deficient RAG2
2/2cc
2/2 mouse model lacks
mature NK cells due to the absence of the receptor c-chain
subunit, which is required for NK cell maturation. The
importance of signaling through the receptor c-chain has been
previously examined in other animal models. Alvarez et al. showed
IL-15 treatment reduced white adipose tissue mass without
altering food intake in leptin-deficient ob/ob mice but not in
leptin receptor-negative fa/fa Zucker rats. These authors de-
termined that IL-15 did not effect adipose tissue in these obese rats
due to a down regulation in receptor c-chain expression [18]. Our
data in RAG2
2/2cc
2/2 mice, on the other hand, demonstrates
that the receptor c-chain is not required for IL-15 to induce weight
loss and reduce adipocyte cell size. This suggests that the c-chain
receptor subunit is dispensable for IL-15 signaling in adipocytes or
compensatory mechanisms may occur in its absence. Although the
Figure 5. IL-15 treatment affects adipocyte size in RAG2
2/2cc
2/2 mice. Representative cross sections of visceral gonadal fat pads excised
from RAG2
2/2cc
2/2 mice treated i.v. with (A) PBS, (B) AdControl, or (C) AdIL-15 were stained with hematoxylin and eosin (H&E). (D) Bar graph shows
cell areas determined under 56objective from each group determined using AxioVision software (n=5 per group). ***P,0.001.
doi:10.1371/journal.pone.0039553.g005
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NKT cell development [32,44], we have previously shown that IL-
15 may mediate its effects in the absence of this receptor subunit
resulting in anti-tumor and anti-viral activity [28,45], as well as in
activating myeloid immune cells [46].
Since IL-15 has been shown to decrease white adipose mass
[19], we believe that acute IL-15 administration may result in
direct lipolysis of adipose tissue, resulting in the release of free fatty
acids into circulation. Alemendro et al. [22] previously showed that
the administration of IL-15 in rats resulted in increased whole
body and skeletal muscle fatty acid oxidation. Increased mRNA
expression of several genes involved in fatty acid oxidation
including carnitine palmitoyltransferase II (CPT-II) and perox-
iome proliferator-activated receptor- d (PPAR-d) in the liver and
skeletal muscle, respectively, demonstrates that IL-15 may induce
the breakdown of fatty acids at peripheral tissues. Whether IL-15
treatment promotes altered mitochondrial function by increasing
fatty acid usage in the liver and skeletal muscle needs to be
determined. Another possible mechanism in which IL-15 may
exert its weight loss effects is through the activation of myeloid
derived cells. Interleukin-15 expression has been reported to alter
macrophage activity in IL-15 tg and IL-15
2/2 mouse models
[28,47]. Adipose tissue macrophages have been shown to alter
insulin sensitivity in adipose tissue [1]. Recently, M2 polarized
macrophages have been found to directly induce lipolysis through
the release of catecholamines in white adipose tissue [48]. Whether
or not IL-15 treatment influences macrophage polarization and
possible secretion of lipolytic factors within white adipose tissue has
yet to be examined. Lastly, rats given a single intravenous injection
of this cytokine had a significant decrease in triglyceride
absorption, without affecting gastric emptying and intestinal
mobility [49]. Therefore, altered intestinal lipid absorption may
in part explain the anti-obesity effects of IL-15.
In conclusion, our data suggest that IL-15 treatment results in
an accumulation of NK, NKT, and CD3 T lymphocytes in
adipose tissue. However, IL-15 mediates weight loss independent
of lymphocyte activation and signaling through the common c-
chain. There is currently a lack of knowledge regarding the effects
of IL-15 on metabolic tissues. Our findings have clear implications
in the field of immuno-metabolism by demonstrating the
importance of immune factors, like IL-15, in regulating adipose
tissue mass. Future studies should continue to focus on de-
termining the mechanism(s) in which IL-15 affects adipocytes.
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